A double-blind placebo controlled trial of modafinil for negative symptoms in schizophrenia

被引：0
作者：
Pierre, J [1 ]
Peloian, JH [1 ]
Wirshing, DA [1 ]
Wirshing, WC [1 ]
Marder, SR [1 ]
机构：
[1] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Geffen Sch Med, Los Angeles, CA 90024 USA
来源：
SCHIZOPHRENIA BULLETIN | 2005年 / 31卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：501 / 501
页数：1
相关论文
共 50 条
[21]   Amoxapine in schizophrenia - A negative double-blind controlled trial [J].
Fitzgerald, PB ;
Filia, S ;
de Castella, A ;
McBain, N ;
Kapur, S ;
Kulkarni, J .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (04) :448-450
[22]   DOUBLE-BLIND PLACEBO-CONTROLLED PILOT TRIAL OF MODAFINIL FOR METHAMPHETAMINE WITHDRAWAL [J].
Lee, Nicole ;
Pennay, Amy ;
Hester, Rob ;
Ferris, Jason ;
Dunlop, Adrian .
DRUG AND ALCOHOL REVIEW, 2009, 28 :A75-A75
[23]   A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia [J].
Mehdi Farokhnia ;
Maryam Sabzabadi ;
Hossein Pourmahmoud ;
Mohammad-Reza Khodaie-Ardakani ;
Seyed-Mohammad-Reza Hosseini ;
Habibeh Yekehtaz ;
Mina Tabrizi ;
Farzin Rezaei ;
Bahman Salehi ;
Shahin Akhondzadeh .
Psychopharmacology, 2014, 231 :533-542
[24]   Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial [J].
Shahin Akhondzadeh ;
Raofeh Ghayyoumi ;
Farzin Rezaei ;
Bahman Salehi ;
Amir-Hossein Modabbernia ;
Azad Maroufi ;
Gholam-Reza Esfandiari ;
Mehrangiz Naderi ;
Fariba Ghebleh ;
Mina Tabrizi ;
Shams-Ali Rezazadeh .
Psychopharmacology, 2011, 213 :809-815
[25]   Adjunctive armodafinil for negative symptoms in adults with schizophrenia: A double-blind, placebo-controlled study [J].
Kane, John M. ;
Yang, Ronghua ;
Youakim, James M. .
SCHIZOPHRENIA RESEARCH, 2012, 135 (1-3) :116-122
[26]   The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial [J].
Iranpour, Negar ;
Zandifar, Atefeh ;
Farokhnia, Mehdi ;
Goguol, Amirhossein ;
Yekehtaz, Habibeh ;
Khodaie-Ardakani, Mohammad-Reza ;
Salehi, Bahman ;
Esalatmanesh, Sophia ;
Zeionoddini, Atefeh ;
Mohammadinejad, Payam ;
Zeinoddini, Arefeh ;
Akhondzadeh, Shahin .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2016, 31 (02) :103-112
[27]   Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: A randomized, double-blind, placebo-controlled, clinical trial [J].
Hosseini, Seyed Mohammad Reza ;
Farokhnia, Mehdi ;
Rezaei, Farzin ;
Gougol, Amirhossein ;
Yekehtaz, Habibeh ;
Iranpour, Negar ;
Salehi, Bahman ;
Tabrizi, Mina ;
Tajdini, Masih ;
Ghaleiha, Ali ;
Akhondzadeh, Shahin .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 (06) :846-855
[28]   Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial [J].
Akhondzadeh, Shahin ;
Ghayyoumi, Raofeh ;
Rezaei, Farzin ;
Salehi, Bahman ;
Modabbernia, Amir-Hossein ;
Maroufi, Azad ;
Esfandiari, Gholam-Reza ;
Naderi, Mehrangiz ;
Ghebleh, Fariba ;
Tabrizi, Mina ;
Rezazadeh, Shams-Ali .
PSYCHOPHARMACOLOGY, 2011, 213 (04) :809-815
[29]   A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia [J].
Farokhnia, Mehdi ;
Sabzabadi, Maryam ;
Pourmahmoud, Hossein ;
Khodaie-Ardakani, Mohammad-Reza ;
Hosseini, Seyed-Mohammad-Reza ;
Yekehtaz, Habibeh ;
Tabrizi, Mina ;
Rezaei, Farzin ;
Salehi, Bahman ;
Akhondzadeh, Shahin .
PSYCHOPHARMACOLOGY, 2014, 231 (03) :533-542
[30]   Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial [J].
Samaei, Areoo ;
Moradi, Kamyar ;
Bagheri, Sayna ;
Ashraf-Ganjouei, Amir ;
Alikhani, Rosa ;
Mousavi, Seiedeh Bentolhoda ;
Rezaei, Farzin ;
Akhondzadeh, Shahin .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2020, 23 (12) :775-782
12345